TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12351939
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol consumption (beer, 40 g/day for men, 30 g/day for women)
Study: 3894256
Drug: Chlorthalidone administered
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone administered at 10h00
Study: 3894256
Drug: Chlorthalidone administered
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone administered at 22h00
Study: 31136662
Drug: Yogurt (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt (220 g/d for 24 weeks)
Study: 31136662
Drug: Milk (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (control group, 220 g/d for 24 weeks)
Study: 29140897
Drug: Slow, sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow, sedative music
Study: 18410686
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture (8 treatment sessions, once a week, at individually selected points)
Study: 18410686
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (normal care)
Study: 15742431
Drug: LY333013 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY333013 (50, 250, and 1000 mg)
Study: 12556067
Drug: LPS stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS stimulation (100 ng/mL) after overnight dwells with Lac-PDF
Study: 12556067
Drug: LPS stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS stimulation (100 ng/mL) after overnight dwells with Bic-PDF
Study: 12556067
Drug: LPS stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS stimulation (100 ng/mL) after overnight dwells with Bic Hi-PDF
Study: 12556067
Drug: LPS stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS stimulation (100 pg/mL) after overnight dwells with Lac-PDF
Study: 12556067
Drug: LPS stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS stimulation (100 pg/mL) after overnight dwells with Bic-PDF
Study: 12556067
Drug: LPS stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS stimulation (100 pg/mL) after overnight dwells with Bic Hi-PDF
Study: 10850898
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment control
Study: 3276271
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (various drugs or drug combinations)
Study: 3276271
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics effective against oral microflora, especially anaerobic bacteria
Study: 3276271
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics against gram-negative aerobic bacteria
Study: 3276271
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic administration
Study: 3276271
Drug: Prolonged administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged administration of antibiotics
Study: 23099796
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with risedronate (35 mg weekly) and teriparatide (20 μg subcutaneously daily)
Study: 23099796
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg subcutaneously daily)
Study: 31028957
Drug: Risedronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (35 mg weekly)
Study: 23099796
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with risedronate and teriparatide
Study: 23099796
Drug: All therapies
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All therapies (combination, teriparatide, risedronate)
Study: 18398097
Drug: TAC (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (docetaxel at 75 mg/m², doxorubicin at 50 mg/m², cyclophosphamide at 500 mg/m²)
Study: 18398097
Drug: NX (vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX (vinorelbine at 25 mg/m² and capecitabine at 2000 mg/m²)
Study: 10879332
Drug: Intravenous 10%
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 10% invert sugar
Study: 10879332
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution with 5% dextrose (D5LR)
Study: 30326932
Drug: well-being therapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: well-being therapy
Study: 22508148
Drug: Esomeprazole alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole alone (40 mg per day)
Study: 22508148
Drug: Esomeprazole plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole plus aspirin (40 mg per day + 100 mg per day)
Study: 15805317
Drug: Oxycodone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (5 mg orally) with acetaminophen
Study: 15805317
Drug: Hydrocodone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone (5 mg orally) with acetaminophen
Study: 10601173
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg/day for 48 hours)
Study: 7588349
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (N-butyl-2-cyanoacrylate and ethanolamine oleate)
Study: 1952471
Drug: Cefoperazone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (3 g every 12 hours) plus piperacillin (75 mg/kg every 6 hours)
Study: 1952471
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g every 8 hours) plus piperacillin (75 mg/kg every 6 hours)
Study: 1952471
Drug: Imipenem alone
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem alone (1.0 g or 0.5 g every 6 hours)
Study: 1952471
Drug: Imipenem (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (4 g/d)
Study: 1952471
Drug: Imipenem (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (2 g/d)
Study: 1952471
Drug: Double beta-lactam
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double beta-lactam therapy
Study: 7191790
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g epicillin plus 1 g probenecid
Study: 7191790
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g epicillin alone
Study: 7191790
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g epicillin, 1 g cephradine plus 1 g probenecid
Study: 7191790
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g epicillin and 1 g cephradine
Study: 30772993
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-inflammatory drugs only)
Study: 22018679
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg once daily)
Study: 23141817
Drug: Exenatide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (2 mg once weekly)
Study: 19083426
Drug: Pycnogenol (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (125 mg daily)
Study: 16412552
Drug: 50mg prednisolone
Normalized name: prednisolone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg prednisolone intravenously twice a day
Study: 11052521
Drug: Inulin supplementation
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin supplementation (24 g daily for three weeks)
Study: 11052521
Drug: Inulin treatment
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin treatment
Study: 8774268
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (280 mg/day)
Study: 1290314
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg daily from the third postoperative day, increasing to 20 mg daily after 1 week for 11 weeks
Study: 26548675
Drug: Osteoporosis education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoporosis education program (six-weekly education sessions)
Study: 14514973
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 and carboplatin AUC = 6 with amifostine 910 mg/m2 (group B)
Study: 1316074
Drug: Lomefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (400 mg orally once daily for 7-10 days)
Study: 1316074
Drug: TMP/SMX (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMX (160 mg/800 mg orally twice daily for 7-10 days)
Study: 26045250
Drug: Denicotinized cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denicotinized cigarettes (DNCs) used ad libitum over 2 weeks in addition to standard treatment (ST)
Study: 26045250
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) alone
Study: 18541548
Drug: n‐3 FAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 FAs group (1.7 g DHA and 0.6 g EPA)
Study: 16758479
Drug: Riluzole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (200 mg/day)
Study: 12680887
Drug: Quazepam 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 20 mg after fasting overnight
Study: 12680887
Drug: Quazepam 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 20 mg 30 min after eating a standard meal
Study: 12680887
Drug: Quazepam 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 20 mg 3 h after eating a standard meal
Study: 9004103
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine 10-40 mg/day, captopril 12.5-50 mg/day, hydrochlorothiazide 12.5-50 mg/day as necessary)
Study: 1310374
Drug: Fish-oil supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil supplement (1.6 g EPA/d and 0.32 g DHA as triglycerides)
Study: 1310374
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fish-oil supplement)
Study: 6395815
Drug: Tinidazole 600
Normalized name: Ofloxacin 200 mg and tinidazole 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 600 mg twice daily for five days
Study: 6395815
Drug: Metronidazole 800
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 800 mg three times daily for five days
Study: 26508531
Drug: FIFA 11+
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIFA 11+ Kids intervention (15-min warm-up programme, twice a week for 10 weeks)
Study: 26508531
Drug: Standard warm-up
Normalized name: Camphor (Synthetic) 5 mg in 100 g TOPICAL CREAM [ALLG Essentials Warm-up Accelerator]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard warm-up (sham treatment)
Study: 22924354
Drug: Acacia arabica
Normalized name: Acacia arabica
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acacia arabica gel
Study: 20731975
Drug: Computer-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based training version of cognitive-behavioral therapy
Study: 11927475
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at a rate of 0.1 microg x kg(‐1) x min(‐1) for 20 min
Study: 11927475
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion in renal failure group
Study: 11927475
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion in control group
Study: 10188118
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Xeroform gauze, daily wound care)
Study: 7004050
Drug: Oral PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral PGE2 (0.5 mg initial dose, followed by 1.0 mg at hourly intervals for up to 24 hours)
Study: 7004050
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of oxytocin (dose increased stepwise up to 20 mIU/min)
Study: 7004050
Drug: Oral PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral PGE2 or intravenous infusion of oxytocin combined with early amniotomy
Study: 7004050
Drug: Oral PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral PGE2 or intravenous infusion of oxytocin
Study: 30388320
Drug: Triptorelin 22.5
Normalized name: triptorelin 22.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 22.5 mg/24 week depot injections
Study: 21232631
Drug: Omega-3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 group (6 g/day of fish oil for ≥1 month)
Study: 19133920
Drug: Desloratadine (DL)
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine (DL) 5 mg/day (continuous)
Study: 17340895
Drug: Titanium oxide
Normalized name: Titanium oxides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium oxide (TiO) implants
Study: 17340895
Drug: Both TiO
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TiO and machined implants
Study: 17340895
Drug: Machined implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined implants in distal positions
Study: 8056732
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) 200 mg daily in divided doses
Study: 2737733
Drug: Dilevalol 200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 200-400 mg daily
Study: 2737733
Drug: Atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50-100 mg daily
Study: 31398669
Drug: Physostigmine salicylate
Normalized name: PHYSOSTIGMINE SALICYLATE
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine salicylate (0.04 mg/kg initial dose, followed by continuous infusion of 1 mg/h for up to 120 h)
Study: 28441944
Drug: Cash transfer
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cash transfer program (CTP) of US$40 monthly for 6 months
Study: 26493793
Drug: carlumab 1
Normalized name: sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: carlumab 1 mg·kg(‐1)
Study: 26493793
Drug: carlumab 5
Normalized name: Carlumab
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carlumab 5 mg·kg(‐1)
Study: 26493793
Drug: carlumab 15
Normalized name: Carlumab
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carlumab 15 mg·kg(‐1)
Study: 24298731
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg once daily) after initial heparin (5 days)
Study: 24298731
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR of 2.0-3.0) after initial heparin (5 days)
Study: 24298731
Drug: Edoxaban (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (30 mg once daily)
Study: 21486803
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of N(G)-nitro-L-arginine methyl ester (L-NAME) for 5 min to inhibit NOS during continuous SS hypoxia
Study: 21486803
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ketorolac for 5 min to inhibit COX during continuous SS hypoxia
Study: 21486803
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ketorolac during SS hypoxia
Study: 21486803
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of L-NAME during continuous SS hypoxia
Study: 18278987
Drug: Risperidone augmentation
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone augmentation
Study: 16677167
Drug: Camostat mesilate
Normalized name: Camostat mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesilate 200 mg three times daily
Study: 11174691
Drug: Detuned ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detuned ultrasound treatment (placebo)
Study: 9413706
Drug: Metrifonate (loading/maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (loading/maintenance dosages 2/0.65 mg/kg/day for 2 and 10 weeks)
Study: 3680568
Drug: Ciramadol 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol 90 mg
Study: 30792154
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg twice daily
Study: 24760401
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl (IPE) 4 g/day co-administered with warfarin 25 mg
Study: 24760401
Drug: Warfarin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 25 mg without IPE
Study: 18942671
Drug: Increased co-payments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased co-payments for PBS medicines (24% increase in January 2005)
Study: 18942671
Drug: Increased co-payments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased co-payments for PBS medicines
Study: 15966872
Drug: Gracey curettes
Normalized name: Graceful catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gracey curettes (CC group)
Study: 11878061
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril and losartan
Study: 11055597
Drug: Ceftibuten (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (once daily for 5 days)
Study: 9346386
Drug: Type-specific antibodies
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type-specific antibodies detection
Study: 8455312
Drug: Casein-based enteral
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein-based enteral nutrition product (1000 kcal, 34 g of proteins)
Study: 3954936
Drug: Brotizolam with
Normalized name: brotizolam
DrugBank: Brotizolam (DB09017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam with ethanol (0.25 mg dose)
Study: 15733875
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 50 mug orally every 4 h
Study: 15733875
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone 0.5 mg every 6 h
Study: 12938066
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of amitriptyline
Study: 12938066
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of mirtazapine
Study: 31570179
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg L-DOPA
Study: 18450126
Drug: Echinacea (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea (3 capsules twice daily for 8 weeks)
Study: 18450126
Drug: Placebo (parsley,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (parsley, 3 capsules twice daily for 8 weeks)
Study: 16621618
Drug: Intravenous methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methyl prednisolone for 5 days along with antiepileptic drug
Study: 16621618
Drug: Antiepileptic drug
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drug monotherapy
Study: 14615654
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 to 60,000 U once weekly (QW)
Study: 14615654
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 100 to 300 U/kg three times weekly (TIW)
Study: 9157582
Drug: Combined prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined prescription and monitoring charts for heparin
Study: 9157582
Drug: Combined prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined prescription and monitoring charts for warfarin
Study: 1286541
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting crystalline zinc insulin
Study: 23940000
Drug: Topical atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical atorvastatin 1% ointment applied once/day for 14 days
Study: 20038732
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of chemotherapy
Study: 20038732
Drug: Five courses
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five courses of chemotherapy
Study: 14638354
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 units, s.c. once weekly)
Study: 14638354
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) for anemia management (RBV dose reduction or discontinuation, transfusions)
Study: 10972451
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for panic disorder, 12 hours in addition to regular alcoholism treatment program.
Study: 10972451
Drug: Regular alcoholism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular alcoholism treatment program (Control group).
Study: 1738796
Drug: Physostigmine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.75 mg SC)
Study: 1738796
Drug: Hyoscine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine (1.2 mg)
Study: 2121574
Drug: Flecainide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (200 mg)